81 related articles for article (PubMed ID: 16721384)
21. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
23. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
24. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Kreuzer KA; Le Coutre P; Landt O; Na IK; Schwarz M; Schultheis K; Hochhaus A; Dörken B
Ann Hematol; 2003 May; 82(5):284-9. PubMed ID: 12692682
[TBL] [Abstract][Full Text] [Related]
25. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
26. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
27. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
28. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Tauchi T; Oyashiki K
Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
[No Abstract] [Full Text] [Related]
29. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
30. Imatinib resistance due to a novel tri-nucleotide insertion in the SH2/C lobe interface of BCR/ABL kinase domain between position K357 and N358.
Vaidya S; Sonawani A; Idicula-Thomas S; Vundinti BR; Ghosh K
Leuk Res; 2012 May; 36(5):e110-2. PubMed ID: 22387050
[No Abstract] [Full Text] [Related]
31. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994
[No Abstract] [Full Text] [Related]
32. Resistance to imatinib: mutations and beyond.
La Rosée P; Deininger MW
Semin Hematol; 2010 Oct; 47(4):335-43. PubMed ID: 20875550
[TBL] [Abstract][Full Text] [Related]
33. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
[TBL] [Abstract][Full Text] [Related]
34. Genzyme launches diagnostic to monitor Gleevec resistance.
Pharmacogenomics; 2006 Apr; 7(3):267. PubMed ID: 16610938
[No Abstract] [Full Text] [Related]
35. Exploiting oxidative damage to overcome resistance.
Karp JE; Smith BD
Leuk Res; 2006 Oct; 30(10):1213-4. PubMed ID: 16564572
[No Abstract] [Full Text] [Related]
36. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
37. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
38. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Marin D; Kaeda J; Szydlo R; Saunders S; Fleming A; Howard J; Andreasson C; Bua M; Olavarria E; Rahemtulla A; Dazzi F; Kanfer E; Goldman JM; Apperley JF
Leukemia; 2005 Apr; 19(4):507-12. PubMed ID: 15703781
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of resistance of leukemia to imatinib mesylate.
Tauchi T; Ohyashiki K
Leuk Res; 2004 May; 28 Suppl 1():S39-45. PubMed ID: 15036940
[TBL] [Abstract][Full Text] [Related]
40. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Schnittger S; Bacher U; Dicker F; Kern W; Alpermann T; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2010 Oct; 49(10):910-8. PubMed ID: 20607847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
